Piper Sandler on Climb Bio (CLYM): 'Upcoming HV data has the potential to unlock significant value'
Tweet Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $23.00 price target on Climb Bio (NASDAQ: CLYM).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
